December 17, 2021
Life Sciences
  • Regeneron Pharmaceuticals said its monoclonal antibody treatment for COVID-19 has “diminished potency” against the omicron variant but remains effective against delta. The drugmaker also said it is working on next-generation drugs that could protect against omicron and be available in 2022. Meanwhile, AstraZeneca PLC said that a lab study showed its own antibody cocktail “retained neutralizing activity” against omicron. (Article here)